{"resourceType":"ValueSet","id":"shr-oncology-BrcaReceptorStatusVS","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>SHR BrcaReceptorStatusVS ValueSet</b></p>\n<p>Classification of receptor status in breast cancer.</p>\n</div>"},"url":"http://standardhealthrecord.org/shr/oncology/vs/BrcaReceptorStatusVS","identifier":[{"system":"http://standardhealthrecord.org","value":"shr.oncology.BrcaReceptorStatusVS"}],"version":"0.0.1","name":"SHR BrcaReceptorStatusVS ValueSet","title":"SHR BrcaReceptorStatusVS ValueSet","status":"draft","date":"2017-12-20","publisher":"The MITRE Corporation: Standard Health Record Collaborative","contact":[{"telecom":[{"system":"url","value":"http://standardhealthrecord.org"}]}],"description":"Classification of receptor status in breast cancer.","compose":{"include":[{"system":"http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS","concept":[{"code":"luminal_A","display":"Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy."},{"code":"luminal_B","display":"Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2."},{"code":"HER2_positive","display":"Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2."},{"code":"Triple_negative","display":"Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy."}]}]}}